Analysts Set Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Price Target at $48.00

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have earned an average rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $48.00.

AAPG has been the subject of several recent research reports. Oppenheimer assumed coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They set an “outperform” rating and a $45.00 target price for the company. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Thursday, March 26th. Finally, Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in AAPG. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International in the third quarter valued at $383,000. XY Capital Ltd lifted its position in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares in the last quarter. UBS Group AG boosted its stake in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. ABC Arbitrage SA bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $204,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $96,000.

Ascentage Pharma Group International Price Performance

AAPG opened at $26.28 on Monday. The company’s 50 day simple moving average is $23.90 and its 200-day simple moving average is $29.48. Ascentage Pharma Group International has a one year low of $17.56 and a one year high of $48.45. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The firm had revenue of $24.72 million during the quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.